A multi-centre, randomised, double-blind, placebo-controlled, parallel group study of the efficacy, safety and tolerability of perampanel in levodopa treated Parkinson's disease patients with motor fluctuations.

Trial Profile

A multi-centre, randomised, double-blind, placebo-controlled, parallel group study of the efficacy, safety and tolerability of perampanel in levodopa treated Parkinson's disease patients with motor fluctuations.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2014

At a glance

  • Drugs Perampanel (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 19 Oct 2012 Planned number of patients changed from 900 to 1260.
    • 09 Dec 2011 Primary endpoint 'Off-time' has not been met.
    • 10 Apr 2008 Status changed from recruiting to completed as reported by Eisai.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top